Autoinjectors, also called auto-injectors, are medical devices designed to deliver a drug dose through the subcutaneous or intramuscular route of administration. According to MarketStack, the Global Autoinjectors Market is expected to grow considerably during the forecasted period. Factors such as the surging incidence of chronic diseases such as diabetes, rheumatoid arthritis, and multiple sclerosis are expected to drive the Global Autoinjectors Market in the forecasted period. Further, the increase in the prevalence of targeted therapies, such as alemtuzumab (certain chronic leukaemias) and trastuzumab (certain breast cancers), is expected to drive the Global Autoinjectors Market in the forecasted period. Furthermore, the rising occurrence of anaphylaxis, consumer preference for self-administration of drugs, and easy accessibility of generic autoinjectors are expected to drive the Global Autoinjectors Market in the forecasted period. However, lack of understanding about the use of an autoinjector, as well as the availability of many other healthcare treatment choices, like oral pills, are some factors that may hinder autoinjector market revenue growth in the forecast period.

Autoinjectors are widely used for epinephrine self-administration (to prevent anaphylaxis), by migraine sufferers (for immediate pain relief), or for medical and emergency treatments.

The rheumatoid arthritis (RA) segment is anticipated to account for a significant revenue share in the forecasted period due to the surging prevalence of this disease. The factors propelling the market growth include increasing demand for patients' convenience and rising incidence of chronic and lifestyle diseases. Rheumatoid arthritis is an autoimmune disease in which the body's immune system attacks the joints, causing inflammation of the synovium and swelling and pain in and around the joints. Arthritis primarily affects older people, with females having a higher prevalence than males. Most of the patients with rheumatoid arthritis who used an autoinjector for the treatment were observed to be comfortable using the device and even had better outcomes than those who had someone else administer injections. Autoinjector devices are highly useful in reducing dependency on medical experts to some level, as these are used to help the dosage of a particular medicine. These tools lessen the risk of noodle sock injuries and widespread fear of needles among patients, thus increasing the need for autoinjectors. Autoinjector tools, such as pen injectors, provide various benefits for multiple applications employed in different medical situations. For immediate medication, there is a high demand for autoinjectors. With autoinjectors, the patient uses pressure on injections to trigger the needle and subsequent bow of medicine, making them easy to use. Furthermore, autoinjectors are often used by people with long-term illnesses who need to take medication daily to manage their symptoms.

North America is expected to hold a significant share of the global disposable auto-injectors market in the forecast period. Factors such as the early adoption of technologically advanced products and product approvals and the increasing prevalence of chronic diseases boost the auto injector market in the region. A high incidence of chronic conditions, such as cancers, grows the market in the area. The increasing prevalence of targeted therapies majorly drives the growth of the global auto injectors market, the growing occurrence of anaphylaxis, surging consumer preferences for self-administration of drugs, advantages of usability, the rising number of regulatory body approvals, government assistance, the easy accessibility of generic autoinjectors, and advantageous reimbursements, and advancement of technology and others. The prevalence of allergic conditions, including severe allergies and anaphylaxis, has also contributed to the rise in global autoinjector market demand. Anaphylaxis is a life-threatening allergic reaction that demands immediate administration of epinephrine (adrenaline). Autoinjectors, like EpiPens, are specifically designed to deliver precise doses of epinephrine during an anaphylactic emergency. An increase in awareness about anaphylaxis and the significance of timely treatment has induced individuals with allergies and their caregivers to choose autoinjectors as an important tool in managing and responding to allergic actions.

Disposable autoinjectors provide convenience and simplicity to both patients and healthcare providers. These devices are pre-filled with a specific medication dosage, eliminating the manual measurement requirement. Patients can easily self-administer their medication without the struggle of handling needles, drawing up doses, or dealing with vials and syringes. This simplicity makes disposable autoinjector highly preferred, especially for individuals with limited experience or skill in medication administration. Disposable autoinjectors provide developed safety features. These are designed to be single-use devices, securing sterility and reducing the risk of needlestick injuries. Once the medication is administered, the autoinjector is discarded, removing the need for needle disposal or cleaning procedures. Anaphylaxis is treated with epinephrine as the first line of defence. Pharmaceutical companies are developing technologically enhanced epinephrine autoinjectors (EAIs) for anaphylaxis. This technological advancement includes portable devices, autoinjectors with two auto-injectable doses in one device, innovative designs, temperature-stabilized autoinjectors and longer span life for epinephrine, gadgets that alert patients when an amount has been administered effectively and others. Therefore, such technological advancements are expected to drive the demand for auto injectors in the forecasted period, contributing towards global market growth.

The market players are AbbVie Inc., Amgen, AstraZeneca, Bayer, and Becton. 

In May 2022, Jabil Healthcare, a division of Jabil Inc., launched the Qfinity autoinjector platform, a reusable, simple, and modular solution for subcutaneous (SC) drug self-administration at a minimum cost than market alternatives.

In May 2022, Stevanato Group S.p.A . signed an exclusive agreement with one of the leading medical device developers and manufacturers, Owen Mumford Ltd., for its Aidaptus auto-injector.

Our Global Autoinjectors Market report provides deep insight into the current and future state of the market across various regions. Also, the study comprehensively analyzes the Autoinjectors Market by segments based on the Application (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis, and Others), Type (Disposable Autoinjectors and Reusable Autoinjectors), End User (Home Care Settings, Hospital and Clinics, and Others), and by Geography (Asia Pacific, North America, Europe, South America, and Middle-East and Africa). The report examines the market drivers and restraints, along with the impact of COVID-19, are influencing the market growth in detail. The study covers & includes emerging market trends, market developments, market opportunities, market size, market analysis, market dynamics, and challenges in the industry. This report also covers extensively researched competitive landscape sections with profiles of prominent companies, including their market share and projects.